Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
UCB’s 90-year book is a goldmine to discover!
Twitter Feed
-
We are delighted to announce that the Patient Value Summit will be held on February 21st in Brussels. The event will bring together thought leaders to discuss a patient-centric healthcare model. ➡️Learn more here: https://t.co/LFRjSkRf4A #InspiredByP
— UCB News (@ucb_news) 19.02.2019 -
75% of patients’ unmet needs are emotional not medical, according to a new study in @nejmcatalyst https://t.co/Yf1N5iQpmC #InspiredByPatients #DrivenByScience https://t.co/O9739Qe9Ym
— UCB News (@ucb_news) 19.02.2019 -
Our new five-year collaboration with the UK @epilepsysociety aims to address needs of people with epilepsy who do not respond to currently available treatments. Find out more about it here: https://t.co/p1Rr0oqLEO #StrongerTogether #HarnessingGenetics
— UCB News (@ucb_news) 18.02.2019
Highlights
At UCB, we take our responsibility to the planet very seriously.
UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. Discove more...
